Treatment Volume, Dose Prescription and Delivery Techniques for Dose-intensification in Rectal Cancer: A National Survey

Caravatta, L.; Lupattelli, Marco; Mantello, G.; Gambacorta, Maria Antonietta; Chiloiro, G.; Tommaso, M. Di; Rosa, Consuelo; Gasparini, L.; Morganti, Alessio Giuseppe; Picardi, V.; Niespolo, R.M.; Osti, Mattia Falchetto; Montrone, S.; Simoni, N.; Boso, Caterina; Facchin, Francesca; Deidda, Maria Assunta; Piva, Cristina; Guida, Cesare; Ziccarelli, L.; Muñoz, Fernándo; Ivaldi, Giovanni Battista; Marchetti, V.; Franzone, P.; Spatola, Corrado; Franco, Pierfrancesco; Donato, Vittorio; Genovesi, Domenico

doi:10.21873/anticanres.14966

Cited by 7 publications

(2 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Colorectal cancer is one of the most common cancer types worldwide (1). Standard treatment for rectal cancer (at least of the lower and middle third) includes radiotherapy or radiochemotherapy of the primary tumor region and the locoregional lymph nodes (2,3). This applies also to the treatment of cancer of the anal canal (4,5).…”

mentioning

confidence: 99%

Evaluation of Pre-radiotherapy Sleep Disorders in Patients With Rectal or Anal Cancer

et al. 2021

View full text Add to dashboard Cite

Background/Aim: Radiotherapy and radiochemotherapy are common treatments for rectal and anal cancer. Anticipation of treatment may cause distress and sleep disorders. This study aimed to identify risk factors for sleep disorders. Patients and Methods: In 42 patients with rectal or anal cancer scheduled for radiotherapy, 16 characteristics were analyzed for associations with pre-radiotherapy sleep disorders including age, gender, performance score, comorbidity, patient's or family history of additional cancer/melanoma, distress score, emotional/physical/practical problems, tumor site and stage, surgery and relation to COVID-19 pandemic. Results: Overall prevalence of pre-radiotherapy sleep disorders was 42.9%. Sleep disorders were significantly associated with Karnofsky performance score 60-80 (p=0.044), Charlson comorbidity index ≥3 (p=0.0012), distress score 6-10 (p=0.00012), and more emotional (p=0.0012), physical (p=0.0004) or practical (p=0.033) problems. A trend was found for female gender (p=0.061). Conclusion: Sleep disorders were common in patients with rectal or anal cancer scheduled for radiotherapy. Risk factors can help identify patients requiring psychooncological support already prior to the start of radiotherapy.

show abstract

mentioning

confidence: 99%

Evaluation of Pre-radiotherapy Sleep Disorders in Patients With Rectal or Anal Cancer

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Rectal cancer persists as one of the most frequently diagnosed cancers and a leading cause of cancer-related death worldwide [ 1 , 2 ]. Treatment paradigms have evolved with the advent of state-of-the-art radiation therapy (RT) technologies, as well as more sophisticated surgical techniques and more efficacious chemotherapeutic agents [ 3 – 7 ]. Neoadjuvant chemoradiation therapy (CRT) followed by total mesorectal excision (TME) surgery and postoperative adjuvant chemotherapy is the current standard of care for patients with locally advanced rectal cancer [ 8 – 10 ].…”

Section: Introductionmentioning

confidence: 99%

Simultaneous Integrated Boost Volumetric Modulated Arc Therapy for Rectal Cancer: Long-Term Results after Protocol-Based Treatment

Lee

Ahn

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

Background. Volumetric modulated arc therapy (VMAT) with simultaneous integrated boost (SIB) is an advanced form of radiotherapy (RT) technology. The purpose of this study was to report long-term treatment outcomes in patients with locally advanced rectal cancer undergoing VMAT-SIB based concurrent chemoradiotherapy (CRT). Methods. Between January 2016 and January 2018, a total of 22 patients with operable stage II-III rectal adenocarcinoma were recruited for the pre-designed VMAT-SIB RT protocol. All patients underwent standard diagnostic and staging work-up. The RT target volumes included the following areas: PTV1 = mesorectum that contained gross tumors and enlarged lymph node regions and PTV2 = mesorectum and regional lymphatics from L4-5/S1 to 3-4 cm below the tumor or levator ani muscle, excluding PTV1. The VMAT-SIB dose prescription was as follows: PTV1 = 52.5 Gy/daily 2.1 Gy/25 fractions, PTV2 = 45 Gy/daily 1.8 Gy/25 fractions. Results. The mean age of the study population was 64 (range, 18-84) years, and 15 (68.2%) patients were male. Radical operation (total mesorectal excision) was performed by either low anterior resection, ultralow anterior resection, or abdominal perineal resection. All five (22.7%) of the patients with confirmed increasing serum carcinoembryonic antigen (CEA) level at diagnosis showed normalization of serum CEA level after the planned treatment. Among 20 patients who underwent preoperative CRT and surgery, tumor down staging in T- and N-stages was achieved in 10 patients (50%) and 13 patients (65%), respectively, with 20% of ypT0/Tis. With a median follow-up of 54.2 (range, 22.6-61.1) months, the 5-year disease-free survival, overall survival, and local control rates were 64.6%, 81.8%, and 84.4%, respectively. Five patients developed distant metastasis and one developed local recurrence as a first event. Two cases with anastomosis site leakage, three with adhesive ileus, and two with abscess formation were observed during postoperative periods. Conclusions. The current VMAT-SIB-based CRT protocol provided acceptable treatment and toxicity outcomes.

show abstract

Neoadjuvant chemoradiotherapy for locally advanced rectal cancer with peritumoral abscesses and fistulas

Gordeev¹,

Иванов²,

Федянин

et al. 2021

Strahlenther Onkol

View full text Add to dashboard Cite

Treatment Volume, Dose Prescription and Delivery Techniques for Dose-intensification in Rectal Cancer: A National Survey

Cited by 7 publications

References 48 publications

Evaluation of Pre-radiotherapy Sleep Disorders in Patients With Rectal or Anal Cancer

Evaluation of Pre-radiotherapy Sleep Disorders in Patients With Rectal or Anal Cancer

Simultaneous Integrated Boost Volumetric Modulated Arc Therapy for Rectal Cancer: Long-Term Results after Protocol-Based Treatment

Neoadjuvant chemoradiotherapy for locally advanced rectal cancer with peritumoral abscesses and fistulas

Contact Info

Product

Resources

About